|
Nov 9
|
AstraZeneca CFO: Obesity Market Has a Lot of Potential
|
|
Nov 9
|
Jobless Claims Decreased More Than Expected
|
|
Nov 9
|
AstraZeneca Is Getting Into the Weight-Loss Drug Game. The Stock Needs a Boost.
|
|
Nov 9
|
Pre-Markets Strong on Higher Bond Rates, Mixed Earnings
|
|
Nov 9
|
Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
|
|
Nov 9
|
Father with brain injury sues pharma giant over Covid vaccine ‘defect’
|
|
Nov 9
|
AstraZeneca stays in GLP-1 drug race with new deal
|
|
Nov 9
|
IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
|
|
Nov 9
|
Trending tickers: Disney | Arm | Astrazeneca | S4 Capital
|
|
Nov 9
|
AstraZeneca signs deal for oral obesity drug and lifts profit outlook
|
|
Nov 9
|
UPDATE 1-China health sector sees better sentiment from anti-graft drive - execs
|
|
Nov 9
|
UPDATE 3-AstraZeneca raises stakes in obesity drug race with Eccogene deal
|
|
Nov 9
|
AstraZeneca Raises Core EPS Guidance Despite Profit Miss
|
|
Nov 9
|
Walt Disney, Affirm, AMC Entertainment, Twilio rise premarket; Lyft, Tesla fall
|
|
Oct 3
|
The 10 pharma companies participating in Medicare price negotiations
|
|
Oct 3
|
AstraZeneca pays £350m to settle heartburn drugs lawsuits
|
|
Oct 3
|
AstraZeneca settles heartburn drug lawsuits for $425mn
|
|
Oct 3
|
UPDATE 3-AstraZeneca to pay $425 million to end US lawsuits over heartburn drugs
|
|
Oct 3
|
AstraZeneca to pay $425 million to end US lawsuits over heartburn drugs
|
|
Oct 2
|
J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study
|